I Lost a Friend Yesterday

Samuel S. Thatcher, M.D., Ph.D. wasn’t well-known outside of his field and if you didn’t know anything about infertility, you’d never had heard of Sam. A quiet man, with a wife, and no children, Sam’s legacy was instead the hundreds of families created through his clinic and research.

In May of this year, Sam began his battle with acute myelogeneous leukemia. Knowing Sam, we all thought he’d win. After all, he’d diagnosed himself with a blood smear. But within two months, he’d begun induction therapy, and had lost 50 pounds, as well as the ability to eat, smell or taste. Chemotherapy and blood transfusions followed, as well as initially encouraging results on the re-biopsy. But pneumonia and a host of other problems plagued him, and he needed surgery again, but his platelets were simply too low.
Despite his aggressive treatment at Vanderbilt Cancer Center, Sam never returned to his practice and passed away Friday afternoon, December 18, 2009 in ICU, with his wife Helen nearby.

While those who knew Sam will miss him, the rest of the tragedy of Sam’s passing is how much the world will never learn because a great scientific researcher is gone. As an author of books on reproductive health, his books helped thousands of women.

Today, I am asking his friends to make a donation to honor his memory.

Blog Category: 

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap